Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Inmune Bio (INMB) Receivables - Net (2019 - 2025)

Inmune Bio (INMB) has disclosed Receivables - Net for 6 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 262.74% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, up 262.74% year-over-year, with the annual reading at $4.3 million for FY2025, 47.72% up from the prior year.
  • Receivables - Net hit $4.3 million in Q4 2025 for Inmune Bio, up from $1.7 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $4.3 million in Q4 2025 to a low of $100000.0 in Q1 2021.
  • Historically, Receivables - Net has averaged $1.4 million across 4 years, with a median of $1.2 million in 2024.
  • Biggest five-year swings in Receivables - Net: crashed 96.55% in 2021 and later surged 262.74% in 2025.
  • Year by year, Receivables - Net stood at $100000.0 in 2021, then surged by 1805.0% to $1.9 million in 2023, then tumbled by 38.01% to $1.2 million in 2024, then soared by 262.74% to $4.3 million in 2025.
  • Business Quant data shows Receivables - Net for INMB at $4.3 million in Q4 2025, $1.7 million in Q3 2025, and $2.0 million in Q2 2025.